{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Lucentis+or+Avastin&page=2",
    "query": {
      "intervention": "Lucentis or Avastin",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 25,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Lucentis+or+Avastin&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Lucentis+or+Avastin&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-05T03:27:43.693Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01644513",
      "title": "Evaluation of the Association Between Genetic Load and Response to Anti-VEGF Therapy in AMD Patients",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Age Related Macular Degeneration"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Sequenom, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "55 Years and older"
      },
      "enrollment_count": 196,
      "start_date": "2012-07",
      "completion_date": "2012-12",
      "has_results": false,
      "last_update_posted_date": "2013-02-12",
      "last_synced_at": "2026-10-05T03:27:43.693Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01644513"
    },
    {
      "nct_id": "NCT01253694",
      "title": "Ranibizumab as a Rescue Therapy for Diabetic Macular Edema",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetic Macular Edema"
      ],
      "interventions": [
        {
          "name": "injection of 0.5 mg of Intravitreal Ranibizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "New England Retina Associates",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 0,
      "start_date": "2011-03",
      "completion_date": "2012-07",
      "has_results": false,
      "last_update_posted_date": "2013-05-03",
      "last_synced_at": "2026-10-05T03:27:43.693Z",
      "location_count": 1,
      "location_summary": "Norwich, Connecticut",
      "locations": [
        {
          "city": "Norwich",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01253694"
    },
    {
      "nct_id": "NCT01610557",
      "title": "Ranibizumab and Bevacizumab for Diabetic Macular Edema",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetic Macular Edema"
      ],
      "interventions": [
        {
          "name": "Ranibizumab",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Eye Institute (NEI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 56,
      "start_date": "2012-05",
      "completion_date": "2015-02",
      "has_results": true,
      "last_update_posted_date": "2022-12-09",
      "last_synced_at": "2026-10-05T03:27:43.693Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01610557"
    },
    {
      "nct_id": "NCT01471691",
      "title": "Intravitreal Ranibizumab 0.5MG, or 1.0mg for RVO With Macular Edema Previously Receiving Bevacizumab",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Branch Retinal Vein Occlusion",
        "Central Retinal Vein Occlusion",
        "Macular Edema"
      ],
      "interventions": [
        {
          "name": "ranibizumab 0.5mg",
          "type": "DRUG"
        },
        {
          "name": "ranibizumab 1.0mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hanscom, Thomas, M.D.",
      "sponsor_class": "INDIV",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2011-11",
      "completion_date": "2014-02",
      "has_results": true,
      "last_update_posted_date": "2015-04-29",
      "last_synced_at": "2026-10-05T03:27:43.693Z",
      "location_count": 4,
      "location_summary": "Huntington Beach, California • Long Beach, California • Santa Monica, California + 1 more",
      "locations": [
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01471691"
    },
    {
      "nct_id": "NCT00304954",
      "title": "Infliximab, Sirolimus and Daclizumab to Treat Age-Related Macular Degeneration",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Age-Related Macular Degeneration",
        "Choroidal Neovascularization"
      ],
      "interventions": [
        {
          "name": "Intravenous Daclizumab",
          "type": "DRUG"
        },
        {
          "name": "Intravenous Infliximab",
          "type": "DRUG"
        },
        {
          "name": "Observation",
          "type": "OTHER"
        },
        {
          "name": "Oral Rapamycin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Eye Institute (NEI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": "92 Years",
        "sex": "ALL",
        "summary": "55 Years to 92 Years"
      },
      "enrollment_count": 13,
      "start_date": "2006-02",
      "completion_date": "2010-01",
      "has_results": true,
      "last_update_posted_date": "2016-11-29",
      "last_synced_at": "2026-10-05T03:27:43.693Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00304954"
    },
    {
      "nct_id": "NCT01712035",
      "title": "Neovascular Age-related Macular Degeneration",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Neovascular Age-related Macular Degeneration"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Oregon Health and Science University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "50 Years to 100 Years"
      },
      "enrollment_count": 44,
      "start_date": "2012-10",
      "completion_date": "2017-12-05",
      "has_results": false,
      "last_update_posted_date": "2018-04-05",
      "last_synced_at": "2026-10-05T03:27:43.693Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01712035"
    },
    {
      "nct_id": "NCT01972763",
      "title": "Ranibizumab for Recalcitrant Wet Age-related Macular Degeneration in Eyes Previously Switched From Bevacizumab and/or Ranibizumab to Aflibercept.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Recalcitrant Wet Age-related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "Ranibizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Northern California Retina Vitreous Associates",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2013-10",
      "completion_date": "2018-07",
      "has_results": false,
      "last_update_posted_date": "2019-02-05",
      "last_synced_at": "2026-10-05T03:27:43.693Z",
      "location_count": 1,
      "location_summary": "Mountain View, California",
      "locations": [
        {
          "city": "Mountain View",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01972763"
    },
    {
      "nct_id": "NCT00593450",
      "title": "Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Age Related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "ranibizumab",
          "type": "DRUG"
        },
        {
          "name": "bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 1208,
      "start_date": "2008-02",
      "completion_date": "2015-04",
      "has_results": true,
      "last_update_posted_date": "2017-08-21",
      "last_synced_at": "2026-10-05T03:27:43.693Z",
      "location_count": 59,
      "location_summary": "Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 50 more",
      "locations": [
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00593450"
    },
    {
      "nct_id": "NCT02457975",
      "title": "Photobiomodulation for the Treatment of Diabetic Macular Edema",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Diabetic Retinopathy"
      ],
      "interventions": [
        {
          "name": "670nm PBM",
          "type": "DEVICE"
        },
        {
          "name": "intravitreous VEGF-inhibitors",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "Medical College of Wisconsin",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2015-06",
      "completion_date": "2019-08-30",
      "has_results": false,
      "last_update_posted_date": "2019-09-10",
      "last_synced_at": "2026-10-05T03:27:43.693Z",
      "location_count": 1,
      "location_summary": "Milwaukee, Wisconsin",
      "locations": [
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02457975"
    },
    {
      "nct_id": "NCT01918371",
      "title": "A Retrospective Study of Anti-Vascular Endothelial Growth Factor (VEGF) Injections for Retinal Vein Occlusion or Diabetic Macular Edema",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Retinal Vein Occlusion",
        "Macular Edema"
      ],
      "interventions": [
        {
          "name": "Anti-VEGF",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 323,
      "start_date": "2013-08-02",
      "completion_date": "2014-09-04",
      "has_results": true,
      "last_update_posted_date": "2019-04-18",
      "last_synced_at": "2026-10-05T03:27:43.693Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01918371"
    }
  ]
}